Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA nal ecacy data
A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03
Key abstracts/publications in HER2+ve Breast Cancer
Chairpersons :
Dr. Shyam Agrawal, Dr. S D Banavali
Speaker :
Dr. Amit Kumar